EPO Patent Publication: Anti-Folate Receptor Alpha Antibodies

The European Patent Office has published patent application EP4499697A1 concerning anti-folate receptor alpha antibodies and their methods of use. The application was filed by Zymeworks BC Inc. and lists multiple inventors. This publication is part of the standard patent application process.

EPO Patent EP4499113A1: Polymeric Iron Binding Compositions for Disease Treatment

The European Patent Office has published patent application EP4499113A1 for polymeric iron binding compositions and methods of use for treating diseases associated with excess damaging reactive iron. The patent application was filed by FE PHARMACEUTICALS (CANADA) INC. and lists Bruce E. Holbein, M. Trisha C. Ang, and Roger Gumbau-Brisa as inventors.

Velusetrag Patent for Chronic Intestinal Pseudo-Obstruction Treatment

The European Patent Office has published patent application EP4590303A1 for Alfasigma S.p.A. concerning the use of Velusetrag for treating chronic intestinal pseudo-obstruction. This patent is designated for multiple European states.

EPO Patent Publication EP4630420A1 on NLRP3 Inhibitors

The European Patent Office has published patent application EP4630420A1 concerning inhibitors of NLRP3, with F. Hoffmann-La Roche AG listed as the applicant. This publication details potential new therapeutic compounds and their applications.

EPO Patent Publication: Anticd28 Antibody for Melanoma Treatment

The European Patent Office has published patent application EP4630060A1 concerning a BEAD BOUND ANTICD28 ANTIBODY for the treatment of malignant melanoma. The patent was applied for by Julius-Maximilians-Universität Würzburg and Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. and is designated for multiple European states.

EPO Patent Publication: Adipic Acid Salt Form CCR6 Antagonist

The European Patent Office has published patent application EP4630118A1 concerning a crystalline adipic acid salt form of a CCR6 antagonist. The patent lists Idorsia Pharmaceuticals Ltd as the applicant and includes specific inventors and IPC classifications related to pharmaceutical compounds and their therapeutic uses.

EPO Patent Application: Pharmaceutical Formulation with Echinochrome A Nanofibers

The European Patent Office has published a new patent application, EP4629966A1, concerning a pharmaceutical formulation incorporating echinochrome A within polymeric micro/nanofibers. The application was published on March 18, 2026, and lists the National and Kapodistrian University of Athens as the applicant.

EPO Patent EP4504796A1: Binding Molecules Specific to Human Epidermal Growth Factor Receptor 2

The European Patent Office has published patent application EP4504796A1 concerning binding molecules specific to human epidermal growth factor receptor 2. The patent was filed by The National Institute for Biotechnology in the Negev Ltd. and lists Niv Papo and Lital Ben Naim as inventors.

Dimeric Compounds as Inhibitors of Glycogen Synthase 1 (Gys1)

The European Patent Office has published patent application EP4587118A1 for dimeric compounds that inhibit Glycogen Synthase 1 (Gys1). The application lists Maze Therapeutics, Inc. as the applicant and details various inventors. This publication relates to potential new therapeutic agents.

EPO Patent EP4499055A2: Abietanes and Methods of Making and Using

The European Patent Office has published patent application EP4499055A2 concerning abietanes and methods of making and using them. The patent application was published on March 18, 2026, with The Florida State University Research Foundation, Incorporated listed as the applicant.